The AI Biotech Survival Playbook: Lessons from AbCellera
🧬 The New Reality of AI Biotech Generative AI and DeepMind’s innovations have completely transformed the biotech industry. Looking at what small and mid-sized AI biotech companies like AbCellera Biologics are facing, the survival rules of the AI era become crystal clear. ⚡ The Perfect Storm Facing AbCellera 1. Big Pharma’s Direct Investment Rush In 2026, major pharmaceutical companies completely changed their AI investment strategy. Partnership Details Eli Lilly + Chai Discovery Multi-target biological drug design platform GSK + Noetik $50M upfront for cancer prognosis prediction foundation model Pfizer + Boltz Exclusive model development for small molecule discovery Big Pharma is now skipping the “middleman” and partnering directly with AI platforms. The space for mid-sized biotechs like AbCellera is rapidly shrinking. ...